Copyright
©2013 Baishideng Publishing Group Co.
World J Hepatol. Mar 27, 2013; 5(3): 97-103
Published online Mar 27, 2013. doi: 10.4254/wjh.v5.i3.97
Published online Mar 27, 2013. doi: 10.4254/wjh.v5.i3.97
Table 1 The demographic data of chronic hepatitis C virus patients infected with hepatitis C virus type 4a (sustained virological response vs non-response) after treatment
NR (n = 48) | SVR (n = 56) | P value | |
Age (yr) | 0.004 | ||
min-max | 12-64 | 7-58 | |
mean ± SD | 44.17 ± 10.97 | 37.91 ± 10.91 | |
Gender | 0.9061 | ||
Female | 9 (18.75) | 10 (17.86) | |
Male | 39 (81.25) | 46 (82.14) | |
Weight (kg) | 85.05 ± 13.98 | 78.54 ± 15.10 | 0.025 |
ALT | 89.15 ± 62.70 | 48.39 ± 40.52 | 0.001 |
AFP | 30.56 ± 22.58 | 11.28 ± 15.33 | 0.001 |
Viral load | 686 150.38 ± 680 474.25 | 15 656.09 ± 452 782.09 | 0.001 |
Low fibrosis (F0-F1) (n = 39) | 7 (17.95) | 32 (82.05) | 0.001 |
High fibrosis (F2-F4) (n = 65) | 41 (63.08) | 24 (36.92) | 0.035 |
A0-A1 (n = 71) | 24 (33.8) | 47 (66.2) | 0.006 |
A2-A3 (n = 33) | 24 (72.73) | 9 (27.27) | 0.009 |
Table 2 The percentage of sustained virological response and non-response patients compared with control subjects in various genotypes of low molecular polypeptide-7 gene n (%)
NR (n = 48) | SVR (n = 56) | All patients (n = 104) | Control (n = 33) | |
AA (n = 14) | 9 (64.29) | 5 (35.71) | 14 (13.46) | 3 (9) |
CA (n = 42) | 35 (83.33) | 7 (16.67) | 42 (40.38) | 12 (36.5) |
CC (n = 48) | 4 (8.33) | 44 (91.67) | 48 (46.15) | 18 (54.5) |
Table 3 Sustained virological response and non-response frequencies in various low molecular polypeptide-7 genotypes n (%)
AA (n = 14) | CA (n = 42) | CC (n = 48) | P value | |
NR (n = 48) | 9 (18.75) | 35 (72.92) | 4 (8.33) | 0.001 |
SVR (n = 56) | 5 (8.93) | 7 (12.50) | 44 (78.57) | 0.001 |
Table 4 The relationship of the genotypes of low molecular polypeptide-7 gene polymorphism within different liver fibrosis and activity stages in sustained virological response and non-response groups after treatment n (%)
AA (n = 14) | CA (n = 42) | CC (n = 48) | P value | |
F0 (n = 10) | 1 (10.00) | 2 (20) | 7 (70) | 0.045 |
F1 (n = 29) | 4 (13.79) | 7 (24.14) | 18 (62.07) | 0.004 |
F2 (n = 36) | 4 (11.11) | 14 (38.89) | 18 (50.00) | 0.013 |
F3 (n = 23) | 4 (17.39) | 14 (60.87) | 5 (21.74) | 0.019 |
F4 (n = 6) | 1 (16.67) | 5 (83.33) | 0 (0) | 0.1021 |
A0 (n = 10) | 1 (11.11) | 1 (11.11) | 7 (77.78) | 0.018 |
A1 (n = 29) | 9 (14.52) | 19 (30.65) | 34 (54.84) | 0.001 |
A2 (n = 36) | 3 (11.11) | 18 (66.67) | 6 (22.22) | 0.001 |
A3 (n = 6) | 1 (16.67) | 4 (66.67) | 1 (16.67) | 0.023 |
Table 5 Multivariate analysis of different clinical factors and alleles of low molecular polypeptide-7 gene polymorphism in responders and non-responders hepatitis C virus patients (%)
Regression coefficient | SE | Odds ratio | 95%CI | P value | |
F0-F1 vs F2-F4 | 2.0553 | 0.490 | 0.128 | 0.0490-0.3346 | 0.0001 |
A0-A1 vs A2-A4 | -1.6529 | 0.465 | 0.192 | 0.0771-0.4759 | 0.0004 |
AFP (< 5 ng/mL vs > 5 ng/mL) | -1.4800 | 0.490 | 0.228 | 0.0871-0.5948 | 0.00025 |
CC vs CA + AA | 3.6972 | 0.616 | 40.333 | 12.0719-134.7572 | 0.0001 |
C allele vs A allel | 1.9298 | 0.334 | 6.888 | 3.5800-13.2519 | 0.0001 |
- Citation: Omran MH, Fotouh BE, Youssef SS, Ibrahim NE, Nabil W, Mahdy ESM, Shosha WG, El-Awady MK. Association between low molecular polypeptide 7 single nucleotide polymorphism and response to therapy in hepatitis C virus infection. World J Hepatol 2013; 5(3): 97-103
- URL: https://www.wjgnet.com/1948-5182/full/v5/i3/97.htm
- DOI: https://dx.doi.org/10.4254/wjh.v5.i3.97